## CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Our Impact</td>
</tr>
<tr>
<td>4</td>
<td>From the Desk of the Chairman</td>
</tr>
<tr>
<td>5</td>
<td>Message from the President</td>
</tr>
<tr>
<td>6</td>
<td>Gateway Celebrity Fight Night</td>
</tr>
<tr>
<td>7</td>
<td>Fundraising Highlights</td>
</tr>
<tr>
<td>9</td>
<td>Ways to Give</td>
</tr>
<tr>
<td>10</td>
<td>Gateway Concierge</td>
</tr>
<tr>
<td>11</td>
<td>Research and Grants Update</td>
</tr>
<tr>
<td>12</td>
<td>Researcher Spotlight</td>
</tr>
<tr>
<td>13</td>
<td>Funded Researchers</td>
</tr>
<tr>
<td>14</td>
<td>Donor Recognition</td>
</tr>
<tr>
<td>18</td>
<td>Gateway Leadership</td>
</tr>
<tr>
<td>19</td>
<td>Financial Highlights</td>
</tr>
</tbody>
</table>
ABOUT GATEWAY

Gateway for Cancer Research accelerates practice-changing discoveries in cancer care by harnessing the unrelenting passion of the cancer research community and empowering informed patients to triumph over their disease. Gateway awards grants to clinician-scientists that advance early phase clinical trials at the vanguard of discovery science, bringing breakthroughs to the bedside for patients around the world.

All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.

OUR CHALLENGE

Cancer is a complex, global, public health threat that calls for a worldwide response. Ending cancer as we know it requires a shared vision and collective drive of researchers, physicians and philanthropists to bring to life the novel, patient centered ideas that lead to transformational breakthrough therapies and cures.

Together, we are a gateway to hope for the 18 million people in the world who will receive a cancer diagnosis this year.

OUR IMPACT

At Gateway, it is always and only about the patient. Thanks to generous underwriting by the Stephenson family, an astonishing 99 cents of every dollar donated directly funds transformational cancer clinical trials around the world.

190+ CANCER CLINICAL TRIALS FUNDED WORLDWIDE

60+ ACTIVE STUDIES FOR CANCERS OF ALL TYPES

99 CENTS OF EVERY DOLLAR DIRECTLY FUNDS CANCER RESEARCH

9,900+ PATIENTS ENROLLED IN GATEWAY-FUNDED STUDIES

$95+ MILLION RAISED FOR INNOVATIVE CLINICAL TRIALS

Cancer: A Global Public Health Challenge

18 MILLION PEOPLE in the world are diagnosed with cancer annually.

Cancer accounts for 9.5 MILLION DEATHS worldwide each year.

In the U.S., nearly 1.9 MILLION NEW CANCER CASES will be diagnosed in 2021.

This year it is estimated that more than 600,000 AMERICANS WILL DIE FROM CANCER.

Sources: National Cancer Institute Surveillance, Epidemiology, and End Result Program (SEER) Study; World Health Organization data reported for 2018.
In a year like no other, when the global pandemic brought hardship to all and unimaginable challenges to those facing cancer, my message is simple: THANK YOU. On behalf of patients, families and cancer researchers around the world, thank you for supporting Gateway for Cancer Research in our mission to deliver breakthrough cancer clinical trials that make a meaningful difference in patients’ lives.

For cancer patients and the dedicated physician-researchers who work tirelessly to cure them, three words come to mind: courage, to face cancer; strength, to overcome it; and resilience, to meet the challenges head-on and drive forward with purpose. Never have these words held more meaning, nor has our mission been more urgent, than at this extraordinary moment in world history.

This is also a moment to celebrate our many successes. Since its founding 30 years ago, Gateway has invested more than $95 million in transformative, early phase clinical trials that are changing the face of cancer care NOW. As you read this, thousands of men, women and children participating in Gateway-funded clinical trials are feeling better, living longer, and conquering cancer TODAY.

This is all thanks to you, our generous supporters who have joined us to bring breakthroughs to the bedside for courageous patients around the world who are desperately seeking ways to overcome their cancer.

While we celebrate this milestone in advancing cancer research and patient care, we resoundingly reaffirm that we will not stop demanding more until we end cancer once and for all. Together with you, Gateway will fulfill our shared vision to create a world in which a cancer diagnosis is no longer feared.

As always, with deepest gratitude and appreciation,

Richard J Stephenson
Chairman of the Board
Gateway for Cancer Research
A MESSAGE FROM THE PRESIDENT

Gateway achieved a remarkable milestone in 2021 – Our 30th year of advancing transformational early phase cancer clinical trials that help patients feel better and live longer as we shape a world in which a cancer diagnosis is no longer feared.

We acknowledge the grief and loss the entire world continues to experience as the COVID-19 pandemic evolves. And we are awed by the resilience of our global cancer community in meeting the pandemic’s unprecedented challenges.

Cancer didn’t stop for COVID. Neither did Gateway. At a time when many organizations pulled back, Gateway drove forward with determination. With cancer patients as our singular focus, we launched Extraordinary Measures, an innovative program that brings cancer clinical trials directly to their doorsteps, ensuring patient access to potentially life-saving investigational therapies. Through the extraordinary generosity of our donors, Gateway raised close to $3 million for patient-centered, site-less clinical trials, and through the ingenuity of physician-researchers, these trials are underway. Gateway is energized to fuel the engine of cancer discovery through the pandemic and beyond.

Extraordinary Measures helped us reach another incredible milestone this year: Gateway awarded just under $10 million in grants for innovative clinical trials, each of which holds practice-changing potential and raises the bar in cancer care. That’s the highest one-year amount in Gateway’s 30-year history!

Our success is dependent upon the generosity of supporters who are inspired by the depth and breadth of our mission and share our vision for the future. This year has been one of notable discoveries and accomplishments, none of which would have been possible without you, our generous donors. On behalf of the entire Gateway team and the patients we are privileged to serve, thank you for your commitment and partnership.

Resilience is defined as the ability to recover from or easily adjust to misfortune or change. Together, looking forward, we will persevere in our mission and achieve our ultimate milestone – an end to cancer as we know it.

Warm regards,

Michael Burton
President and CEO
Gateway for Cancer Research
A KNOCK-OUT PUNCH FOR CANCER

This spring, Gateway for Cancer Research and Celebrity Fight Night (CFN) joined forces to expand our collective impact and philanthropic power to defeat cancer.

CFN is an internationally-recognized philanthropic organization whose charity events are synonymous with celebrity support for advances in health and well-being. Since its founding by Jimmy Walker in 1994, CFN has granted more than $90 million to the Barrow Neurological Institute in Phoenix and several other health and wellness nonprofits. Gateway’s Chairman, Richard J Stephenson and Vice Chair, Dr. Stacie J. Stephenson have long been proud sponsors of Celebrity Fight Night and its charitable mission.

The Stephensons now take the helm of CFN to usher in the next era for this incredible event. Sean Currie, who joined CFN in 1997 and has been instrumental in its fundraising success, continues in his role as Executive Director, partnering with Gateway in its mission to fund transformative, patient-centered, clinical cancer research.

In our almost 60-year collective history, our two organizations have raised more than $180 million for medical research that makes a meaningful difference in the lives of so many. The new partnership will only accelerate the realization of Gateway’s vision to end cancer as we know it.

SAVE THE DATE
March 12, 2022 | Phoenix, Arizona
FUNDRAISING HIGHLIGHTS

VINO CON STELLE – AN EVENING UNDER THE STARS

The stars aligned in spectacular fashion on April 23, 2021 at the fourth annual Vino con Stelle, an Arizona fundraising event which raised a record-breaking $772,000 for transformational early phase cancer research.

Vino con Stelle is a world-class culinary, wine and star-studded philanthropic experience that celebrates the breakthrough advances in cancer research and patient care that are made possible when leading cancer researchers, physicians and philanthropists come together with passion and purpose.

Global philanthropists Dr. Stacie J. Stephenson, Vice Chair of Gateway, and Richard J Stephenson, Gateway Founder and Chairman, served as hosts and co-chairs for the event, held at the Royal Palms Resort and Spa in Phoenix. Multiple Emmy Award-winning journalist Tara Hitchcock emceed an amazing event, featuring live performances by recording artists Pia Toscano, Loren Allred, Justin Guarini and William Joseph. Pulitzer Prize-winning author, oncologist and Gateway-funded investigator Siddhartha Mukherjee, MD, DPhil, delivered a keynote address.

Guests enjoyed wines curated by renowned restaurateur Mark Tarbell. Arizona Cardinals wide receiver Larry Fitzgerald was honored with Gateway’s prestigious Leadership in Cancer Advocacy Award, for his outstanding advocacy on behalf of cancer patients and his efforts to advance treatments and cures for cancer.

Gateway extends our deepest gratitude to the Vino con Stelle host committee members and all who came together for an evening under the stars. Thank you for joining us in our life-saving mission to fund the transformative cancer research that will forever change the face of cancer care.
EXTRAORDINARY MEASURES YIELDS EXTRAORDINARY RESULTS

For the nearly 5,000 Americans every day who receive a cancer diagnosis, the global COVID-19 pandemic delivered a double dose of complexity and heartache. Many vulnerable cancer patients opted to delay treatment, and clinical trials were suspended as cancer centers reallocated resources to pandemic response. Countless cancer patients around the world had limited access to clinical trials of promising investigational therapies.

To address this unprecedented threat to cancer care and clinical research, Gateway launched Extraordinary Measures, an innovative grant program to fund “site-less” early phase clinical oncology studies that leverage technologies like telemedicine, wearables and smartphone apps, and remote monitoring to improve patient access to cancer clinical trials.

Extraordinary Measures has raised nearly $3 million for innovative, patient-centered, site-less cancer clinical trials, and has two funded studies currently underway.

Sameek Roychowdhury, MD, PhD, of The James Comprehensive Cancer Center at The Ohio State University, is leading a clinical trial that delivers molecular profiling to the doorsteps of patients with certain rare solid tumor cancers, utilizing telehealth consultation with local oncology practices.

At Princess Margaret Cancer Centre in Toronto, Canada, Gary Rodin, MD, is studying the efficacy of iCALM, an online mental health program to help patients and their caregivers better manage the psychosocial implications of living with advanced cancer, improving quality of life and expanding access for those who cannot attend the in-person CALM program.

Cancer didn’t stop for the pandemic. Thanks to Extraordinary Measures, neither did Gateway. We have additional site-less clinical trial applications currently under review for funding and have extended our search for the most promising patient-centered research until the end of 2021.

We are deeply grateful for the generosity of many donors who seized the opportunity to make a meaningful difference in the lives of those facing cancer at a time of unprecedented need.

30TH ANNIVERSARY CURES GALA – STARDUST DREAMS

We’re getting ready to have a ball! The Cures Gala, co-hosted by Dr. Stacie J. and Richard J Stephenson and held on November 13, 2021, will be an unforgettable celebration of an incredible milestone: Gateway’s 30th year of advancing transformational research that gives those facing cancer and their loved ones more options, more time, and better quality of life.

Since 1991, Gateway has been harnessing the shared passion and collective drive of world-class cancer researchers, physicians and philanthropists to advance innovative, early phase clinical trials, all of which have the potential to make a meaningful difference in patients’ lives. The 30th Anniversary Cures Gala – Stardust Dreams will be a stellar celebration of all that we have achieved, together, in support of our vision: To shape a world in which a cancer diagnosis is no longer feared.

Gateway deeply appreciates your support in making this milestone event the most successful yet. All proceeds will directly support clinical trials funded by Gateway for Cancer Research. For more information, contact Natalie Stewart, Chief Advancement Officer, at natalie.stewart@gatewaycr.org.
WAYS TO GIVE
There are many ways to support Gateway’s vital cause.

Event Sponsorship
Sponsor a Signature Event and make a meaningful impact in the fight against cancer

Make a Donation
Fund any amount to help Gateway advance its vision of shaping a world in which a cancer diagnosis is no longer feared

DIY Fundraiser
Gateway provides all the resources you need for a successful event

In-Kind Gifts
Gifts of merchandise or experiences create excitement at events and provide impactful marketing exposure

Tribute Gifts
Show how much your friend or loved one means to you by making a donation in their honor

Life Insurance
Create an inspirational legacy by naming Gateway as a beneficiary of a life insurance policy that you and your family may no longer need

Stocks
Gifts of stock will help continue Gateway’s funding of lifesaving research

Wills and Bequests
Include Gateway to create a lasting testament to your giving

Gateway Concierge
Tailor a novel research program inspired by your passion to drive innovative discoveries in cancer care

Charitable Trusts
Make a difference by directly supporting cancer trials

Corporate Social Responsibility Partner
Share your passion for funding breakthrough cures through support from your organization

Volunteering
Give the gift of your time by joining a committee or attending an event
Gateway’s exclusive cancer philanthropy experience, Gateway Concierge, ignites visionary collaboration between global philanthropists and world-class clinician-scientists whose breakthroughs are changing the face of cancer care. Launched in 2019, the program aligns high-impact donors who want to make a meaningful difference in the fight against cancer – those who understand the importance of funding early phase research and value the relational nature of personalized philanthropy – with those research leaders who can deliver results.

Through Concierge, Gateway and the donor co-design a novel research program that speaks directly to a donor’s individual experience, passion, and philanthropic intentions to advance cancer research. Gateway then engages the global cancer research community to identify, through rigorous peer review, the most promising research teams who can deliver on the donor’s vision.

Gateway is pleased to announce its fourth Concierge gift, the generous commitment of $250,000 from Joe Caltabiano, CEO and Director, Choice Consolidated Corp. and a member of Gateway’s board of directors. This follows a gift of $250,000 from Andi and Jim Gordon, founder and managing partner of The Edgewater Funds; a $750,000 gift from Muneer Satter, founder and chairman of Satter Investment Management; and the inaugural Concierge gift of $250,000 from healthcare entrepreneur Raj Mantena. We gratefully acknowledge these enterprising philanthropists whose generosity is changing the face of cancer care.

DONOR SPOTLIGHT: RAJ MANTENA, RPh
Chairman and Founder, Integra Connect

As a healthcare entrepreneur in the business of providing specialty practice management services to cancer centers for more than 25 years, inaugural Concierge donor Raj Mantena has firsthand knowledge of the cancer patient’s experience, from diagnosis through treatment and beyond.

“I see the challenging journey cancer patients go through,” Mantena says. “The whole process – which Integra Connect is at the forefront of managing – can be overwhelming. It’s hard not to be affected by the experience of patients and their families.”

With an educational background in clinical pharmacy, Mantena also knows a great deal about the drug development process, and the importance of patient access to early phase clinical trials.

Simply put, “Early phase research saves lives,” he says.

Mantena brings that experience and deep desire to help those facing cancer to his partnership with Gateway in co-creating a research program in precision medicine.

In the broadest sense, precision medicine involves sequencing a patient’s tumor to identify the gene mutations that drive the cancer, then tailoring therapies to target those alterations. To clinician-researchers and those like Mantena, it also means matching a patient with the most promising clinical trial based on the genetics of their individual tumor.

Mantena’s generous gift will support an early phase clinical trial using telemedicine to bring a novel blood-based genomic test – a precision diagnostic – to patients with a rare type of liver cancer. Sameek Roychowdhury, MD, PhD, of The James Comprehensive Cancer Center at The Ohio State University is leading a clinical trial of this “liquid biopsy” that detects and evaluates DNA fragments shed into the blood by the patient’s tumor.

The James oncologists who specialize in treating cholangiocarcinoma use the genomic analysis to match these patients to clinical trials of investigational therapies for their disease. While patients can benefit from the cutting edge genomic testing and clinical expertise found at academic cancer centers like The James, most cannot travel long distances or pay expensive out-of-pocket costs for this expert level of care. Through telemedicine, Dr. Roychowdhury’s clinical trial, made possible by Mantena’s Concierge gift, offers patients expert care and access to the latest personalized therapies for their cancer, and sets the stage for future clinical trials of precision diagnostics for cancer.

“Early phase research gives us the best opportunity for helping patients,” Mantena says. “Even if it were to save only a few lives, or give us a just a few new treatment options, it’s so important. Everyone should champion early phase research.”
THE POWER OF PARTNERSHIPS – A RESEARCH AND GRANTS UPDATE

Gateway invests in innovative early phase research that has the potential to shift the paradigm for standard of care and make a meaningful difference in the lives of cancer patients. Through partnerships with like-minded organizations, Gateway is moving the needle against cancer.

CONQUER CANCER®
THE ASCO FOUNDATION

Gateway’s scientific partnership with the philanthropic foundation of the American Society of Clinical Oncology (ASCO), Conquer Cancer®, advances cancer research through two programs.

• A $50,000 Young Investigator Award (YIA) supports the next generation of clinician-scientists at the beginning of their careers. The 2021 recipient Ivan de Kouchkovsky, MD, of the University of California, San Francisco, is working to develop new targeted treatment approaches for men with advanced, metastatic prostate cancer.

• The prestigious Discovery Grant Program funds a compelling area of inquiry with a $1.5 million grant awarded every two years. Gateway announced the 2022 Discovery Grant which, when awarded, will provide funding to catalyze innovative clinical research with a strong potential impact on mitigating cancer health disparities within underrepresented patient populations and improving equitable access to cancer clinical trials.

NIH NATIONAL CANCER INSTITUTE

Gateway announced a new partnership with the National Cancer Institute (NCI) to support Specialized Programs of Research Excellence (SPORE)/P20 grant recipients with additional funding to complete critical translational research. Highly competitive and prestigious SPORE grants are the NCI’s funding mechanism designed to enable rapid and efficient translation of basic scientific findings into the clinic. The nation’s top multi-disciplinary cancer research teams at leading cancer centers advance breakthrough discoveries for patients through SPORE funding. Gateway has committed $2.5 million in funding for three to four clinical trials in the inaugural year of this program.

SIO Integrative Oncology

Gateway is focused on funding evidence-based integrative oncology research that aims to increase quality of life, especially during and post-treatment. To bring the most promising patient-centered, integrative oncology research proposals forward, Gateway is partnering with SIO to support integrative clinical trials conducted by principal investigators and institutions among its membership. SIO’s mission is to advance evidence-based, comprehensive, integrative healthcare to improve the lives of people affected by cancer.

RISING TIDE
Foundation

Gateway provides scientific review support and post-award grant management services for this Switzerland-based foundation.

EORTC European Organisation for Research and Treatment of Cancer

EORTC is a non-governmental, non-profit organization which unites clinical cancer research experts throughout Europe to advance cancer treatment and improve patients’ quality of life. In 2021, Gateway announced an award over $500,000 to EORTC for an international, 40-site clinical trial evaluating a novel combination molecularly-targeted therapy and radio-chemotherapy to reduce treatment toxicities and improve outcomes for adolescents and adults with a rare brain cancer, medulloblastoma.
RESEARCHER SPOTLIGHT: RACHEL BLITZBLAU, MD, PhD

Pre-operative Breast Radiotherapy: A Tool to Provide Individualized and Biologically-Based Radiation Therapy

While there are several different types of breast cancer, the initial treatment approach is more or less the same for most women – surgery to remove the tumor followed by radiation to destroy any cancer cells that may have been left behind. A Gateway-funded study, led by Rachel Blitzblau, MD, PhD, is moving away from this “one-size-fits-all” radiation therapy toward a more targeted approach based on the genetic characteristics of an individual woman’s tumor.

Dr. Blitzblau and her colleagues at Duke University Cancer Center recently completed a Phase II trial that successfully treated women with radiation before surgery. The main benefit of the pre-surgical approach, she found, is that an intact breast is a more reliable target for radiation therapy, meaning less of the surrounding normal tissue is exposed to high-dose radiation.

“Our goal with radiotherapy is to precisely target the tumor to spare as much healthy tissue as possible from receiving the radiation dose,” Blitzblau says. “We found this much easier to do before surgical removal of the tumor, when the breast was still fully intact. This is reflected in our good patient outcomes.”

Dr. Blitzblau found the pre-operative radiation to be well-tolerated with excellent cosmetic outcomes for patients. The vast majority of patients reported they were very satisfied or extremely satisfied with the pre-operative radiation therapy, and all of them said they would choose this treatment again, if needed.

“For me personally, this was a ‘walk in the park’ part of the breast cancer story. I had no down time during the pre-operative radiation, no side effects. I hope this clinical trial will be available for others that fit the profile because it takes the unexpected out of having breast cancer.”

- Patient of Dr. Blitzblau

In the longer term, Dr. Blitzblau will continue to track patient outcomes in search of opportunities to fine-tune the radiation therapy. She also sees the potential for expanded approaches, such as combining pre-operative radiation therapy with immunotherapy or chemotherapy in higher risk patients, for example.

The ultimate goal of the research is to improve upon current radiation methods that treat all breast cancers alike with an individualized approach based on tumor characteristics. That could be an initial treatment game-changer for millions of women diagnosed with breast cancer.

“I am three years cancer-free, which is the ultimate goal in this process. I would do it all over again,” the patient said. “I hope this radiation treatment will be a part of cancer care going forward.”
<table>
<thead>
<tr>
<th>FUNDED RESEARCHERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Be the Match Foundation</td>
</tr>
<tr>
<td>Dr. Steven Devine</td>
</tr>
<tr>
<td>Boston Children’s Hospital</td>
</tr>
<tr>
<td>Dr. Alexandra Carey</td>
</tr>
<tr>
<td>Children’s Hospital Los Angeles</td>
</tr>
<tr>
<td>Dr. Hisham Abdel-Azim</td>
</tr>
<tr>
<td>Dr. Fariba Navid</td>
</tr>
<tr>
<td>Dr. Nathan Robison</td>
</tr>
<tr>
<td>Dr. Alan Wayne</td>
</tr>
<tr>
<td>Cincinnati Children’s Hospital Medical Center</td>
</tr>
<tr>
<td>Dr. Stella Davies</td>
</tr>
<tr>
<td>Dr. Parinda Mehta</td>
</tr>
<tr>
<td>City of Hope</td>
</tr>
<tr>
<td>Dr. Christine Brown</td>
</tr>
<tr>
<td>Dr. Sumanta Pal</td>
</tr>
<tr>
<td>Cleveland Clinic</td>
</tr>
<tr>
<td>Dr. Miriam Cremer</td>
</tr>
<tr>
<td>Dr. David Levy</td>
</tr>
<tr>
<td>Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>Dr. Toni Choueiri</td>
</tr>
<tr>
<td>Dr. Suzanne Forrest</td>
</tr>
<tr>
<td>Dr. Rachel Freedman</td>
</tr>
<tr>
<td>Dr. Rizwan Romee</td>
</tr>
<tr>
<td>Dr. Jonathan Schoenfeld</td>
</tr>
<tr>
<td>Dr. Sara Tolaney</td>
</tr>
<tr>
<td>Duke University Cancer Center</td>
</tr>
<tr>
<td>Dr. Rachel Blitzblau</td>
</tr>
<tr>
<td>Emory University School of Medicine</td>
</tr>
<tr>
<td>Dr. Craig Hofmeister</td>
</tr>
<tr>
<td>Geneva University Hospital</td>
</tr>
<tr>
<td>Dr. Nicholas Mach</td>
</tr>
<tr>
<td>George Mason University</td>
</tr>
<tr>
<td>Dr. Emanuel Petricoin</td>
</tr>
<tr>
<td>Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute</td>
</tr>
<tr>
<td>Dr. John Levine</td>
</tr>
<tr>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>Dr. Nilofer Azad</td>
</tr>
<tr>
<td>Dr. Lei Zheng</td>
</tr>
<tr>
<td>Karmanos Cancer Institute</td>
</tr>
<tr>
<td>Dr. Abhinav Deol</td>
</tr>
<tr>
<td>Massachusetts General Hospital Cancer Center</td>
</tr>
<tr>
<td>Dr. Marcela Maus</td>
</tr>
<tr>
<td>Dr. David Ting</td>
</tr>
<tr>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Dr. Lorenzo Cohen</td>
</tr>
<tr>
<td>Dr. Ecaterina Ileana Dumbrava</td>
</tr>
<tr>
<td>Dr. Amol Ghia</td>
</tr>
<tr>
<td>Dr. Nancy Gordon</td>
</tr>
<tr>
<td>Dr. Aung Naing</td>
</tr>
<tr>
<td>Dr. Ajay Sheshadri</td>
</tr>
<tr>
<td>Dr. Nizar Tannir</td>
</tr>
<tr>
<td>Dr. Yinghong Wang</td>
</tr>
<tr>
<td>Dr. Shiao-Pei Weathers</td>
</tr>
<tr>
<td>Dr. Shannon Westin</td>
</tr>
<tr>
<td>Dr. Mark Zafereo</td>
</tr>
<tr>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Dr. Connie Batleivi</td>
</tr>
<tr>
<td>Dr. Lee Jones</td>
</tr>
<tr>
<td>Dr. Dana Rathkopf</td>
</tr>
<tr>
<td>Dr. Linda Vahdat</td>
</tr>
<tr>
<td>Ottawa Hospital Research Institute, Canada</td>
</tr>
<tr>
<td>Dr. Rebecca Auer</td>
</tr>
<tr>
<td>Princess Margaret Cancer Centre</td>
</tr>
<tr>
<td>Dr. Gary Rodin</td>
</tr>
<tr>
<td>Royal College of Surgeons</td>
</tr>
<tr>
<td>Dr. Bryan Hennessy</td>
</tr>
<tr>
<td>Rutgers, The State University of New Jersey</td>
</tr>
<tr>
<td>Dr. Isaac Kim</td>
</tr>
<tr>
<td>Seattle Children’s Hospital</td>
</tr>
<tr>
<td>Dr. Sarah Leary</td>
</tr>
<tr>
<td>Sheba Medical Center</td>
</tr>
<tr>
<td>Dr. Yaacov Lawrence</td>
</tr>
<tr>
<td>St. Jude Children’s Research Hospital</td>
</tr>
<tr>
<td>Dr. Michael Bishop</td>
</tr>
<tr>
<td>Dr. Tanja Gruber</td>
</tr>
<tr>
<td>Dr. Jeffrey Rubnitz</td>
</tr>
<tr>
<td>The James Comprehensive Cancer Center at The Ohio State University</td>
</tr>
<tr>
<td>Dr. Maryam Lustberg</td>
</tr>
<tr>
<td>Dr. Sameek Roychowdhury</td>
</tr>
<tr>
<td>The Wistar Institute</td>
</tr>
<tr>
<td>Dr. Dario Altieri</td>
</tr>
<tr>
<td>University of Alabama at Birmingham</td>
</tr>
<tr>
<td>Dr. James Markert</td>
</tr>
<tr>
<td>University Hospital Basel</td>
</tr>
<tr>
<td>Dr. Christoph Mamot</td>
</tr>
<tr>
<td>Dr. Sacha Rothschild</td>
</tr>
<tr>
<td>University Hospital, Inselspital</td>
</tr>
<tr>
<td>Dr. Adrian Ochsenbein</td>
</tr>
<tr>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td>Dr. Sabine Mueller</td>
</tr>
<tr>
<td>University of Iowa</td>
</tr>
<tr>
<td>Dr. Bryan Allen</td>
</tr>
<tr>
<td>University of Michigan</td>
</tr>
<tr>
<td>Dr. Yoshie Umemura</td>
</tr>
<tr>
<td>University of Rochester</td>
</tr>
<tr>
<td>Dr. David Linehan</td>
</tr>
<tr>
<td>University of Texas Southwestern Medical Center</td>
</tr>
<tr>
<td>Dr. Muhammad Beg</td>
</tr>
<tr>
<td>Dr. David Gerber</td>
</tr>
<tr>
<td>Dr. Dominic Moon</td>
</tr>
<tr>
<td>University of Utah</td>
</tr>
<tr>
<td>Dr. Anupam Verma</td>
</tr>
<tr>
<td>Universitaetsklinikum Regensburg (EORTC)</td>
</tr>
<tr>
<td>Dr. Peter Hau</td>
</tr>
<tr>
<td>Yale University</td>
</tr>
<tr>
<td>Dr. Ranjit Bindra</td>
</tr>
</tbody>
</table>
THANK YOU TO OUR DONORS

On behalf of the patients, families, and clinician-scientists around the world for whom your donations are making a difference, thank you for supporting Gateway for Cancer Research and the quest to create a world in which a cancer diagnosis is no longer feared.

Every donor and every dollar make a meaningful difference in the fight against cancer. Your generosity is making possible some of the most innovative, transformational clinical trials that will end cancer as we know it.

CHAIRMAN’S CIRCLE  
$100,000 and Above
Dr. Stacie J. and Mr. Richard J Stephenson  
Cancer Treatment Centers of America®  
Mr. and Mrs. Joseph Caltabiano  
Clune Construction Company  
The Edgewater Funds, Andi and Jim Gordon  
International Private Bank  
Mr. and Mrs. Raj Mantena  
The Marian G. Harrison Trust  
Rising Tide Foundation  
Satter Foundation  
Stellar Insurance  
Templer Family Foundation

VISIONARIES CIRCLE  
$50,000 - $99,000
CTCA Phoenix  
Ms. Mary Gerdts and Mr. Douglas McKinney  
Mr. and Mrs. Jim Hebets, The Comp Consulting Companies  
Mr. and Mrs. Darren P. Keller  
Dr. and Mrs. Christopher Stephenson

CIRCLE OF INNOVATION  
$10,000 - $24,999
Dr. Ed Chu  
Mr. and Mrs. Timothy Flanigan  
Mr. and Mrs. Bill Grogan  
Mr. and Mrs. James Grogan  
Mr. and Mrs. Charles Harris  
The Kelly Foundation  
Mr. and Mrs. Bruce S. Lubin  
Mr. and Mrs. George Lund  
Mr. and Mrs. Dennis Lynde  
Mrs. Lisa McCullagh  
The Honorable Stephen Manrose and Mrs. Janet Horn  
Phoenix Children’s Hospital  
Mr. and Mrs. Tom Reahard  
Mr. and Mrs. Tim Schaub  
The Shirley C. Caris Family Foundation  
Mr. and Mrs. James V. Stibgen  
Mr. and Mrs. Shane Thompson  
University of Phoenix  
Mr. and Mrs. Richard A. York

CIRCLE OF HOPE  
$1,000 - $9,999
Ms. Robyn Andrews  
Arizona Diamondbacks  
Dr. and Mrs. Pat Basu  
Mr. and Mrs. Thomas Blake  
Mr. Matthew Boland and Mr. Christopher Greulich  
Ms. Tanya Bonaparte  
Dr. Tammy Born  
Dr. and Mrs. John Brown  
Mrs. Stella Centeno  
Dr. Robert Childress  
Ms. Yekaterina Chudnovsky  
Mr. and Mrs. Joey Ciolli  
Mr. Michael Cohen  
Mr. and Mrs. Gary Contreras  
Mr. and Mrs. Joe Courtney  
Ms. Zalenda Cyrille  
Mr. and Mrs. Hanley Dawson III  
Mr. and Mrs. Larry Day  
Mr. and Mrs. Fred DeGrandis  
Ms. Horalia Dolmuz  
Mr. and Mrs. Tony Festa  
Mr. Mike Filbin  
Mr. and Mrs. Jacob Flanders  
Mr. Philip Fleischman  
Mr. and Mrs. Dana Garmany  
Mr. and Mrs. Bonsal Glascock  
Mr. and Mrs. John Graham  
Mr. and Mrs. Michael Greenman  
Mr. Todd Halberg  
Mr. and Mrs. Andrew Hammar  
Ms. Cheryl Hintzen-Gaines and Mr. Ira Gaines  
Dr. and Mrs. Jeffrey Hoag  
Mr. and Mrs. William Hubble  
Mr. and Mrs. J.C. Huizenga  
James C. Holleran Jr. Memorial Fund  
Dr. Toufic Kachaamy  
Kate and Ted Emmerich Family Foundation  
Mr. and Mrs. Jeff Katz  
Mr. and Mrs. Matthew Kibbe  
Mr. Ilya Koffman  
Mr. Nicholas Koopalettes  
Mr. and Mrs. Gary Kulibieda  
Mr. and Mrs. Jesse Lopez  
Drs. Cynthia and Stephen Lynch  
Ms. Missie Madeja  
Dr. Patrick McCarthy and Mrs. Lisa Keane McCarthy  
Dr. and Mrs. Robert McCulloch  
Ms. Karen McPartland  
Dr. Jeffrey Metts  
Ms. Metta M. Miller  
Ms. Alycia Mondavi  
Mr. and Mrs. Brent Moser
Ms. Renae Murphy
Ms. Janet Pape
Ms. Jenny R. Patterson and Mr. Steven L. Kroll
Mr. Rich Pemenko
Ms. Deniz Razon and Mr. Kerr Manson
Mr. and Mrs. Max Sanel
Bill Sasso, Stradley Ronon
Mr. and Mrs. David Scheible
Ms. Pamela Schneck
Mr. and Mrs. Jeff Schwartz
ONEHOPE Foundation
Mr. and Mrs. Donald Smith
Mr. Brandon Soerens
Morgan and Shawn Stephenson
Mr. and Mrs. Robert Stockley
Mr. and Mrs. Mark Tarbell
Team National Hope Foundation
Thrivent Financial for Lutherans
Dr. and Mrs. E. Steven Townsend
Dr. and Mrs. Kevin Tulipana
Mr. Jonathan Watkins
Mr. Aaron Wentworth
Mr. and Mrs. Cornel Williams
Dr. and Mrs. Larry Wofford
Dr. and Mrs. Peter C. Yesawich
Dr. and Mrs. Kenny Yoo

CIRCLE OF FRIENDS
$100 - $999
Mr. Carlos Abreu
Ms. Hanah Ali
Mr. Douglas Anderson
Mrs. Jo Ann Andrews
Mr. Eric Armstrong
Ms. Susan Avila
Ms. Emma Azadan
Ms. Adrienne Babb
Mr. and Mrs. Steve Baer
Mrs. Rachel Bailey
Ms. Anna Baird
Ms. Karen Baker
Ms. Rosanne Balasabas
Mrs. Brenda Bantle
Mr. DuWayne Barkema
Ms. Elle Bausch
Mr. Nathaniel Beale
Mr. and Mrs. Henry Berns
Mr. Bryan Berry

Dr. Paul Bessonette
Ms. Leslie Beyer
Mr. Roy Black
Ms. Mary Blackwell
Mr. Brent Blandino
Mr. Dan Blaney
Mr. and Mrs. Lawrence Bloxsom
Mr. John Bogucki
Ms. Mary Bond
Mr. and Mrs. Bob Bondurant
Mr. Randy Bosman
Mr. Daniel Bowline
Ms. Ruth Boyd
Ms. Dolores Braswell
Mr. and Mrs. Daniel Brazas
Mr. Scott Brewer
Mr. Al Briggs
J W Briscoe
Ms. Claudia Bruder
Mr. Philip Bruno
Ms. Elizabeth Burgess
Ms. Melissa Burroughs
Ms. Alaina Butler
Mr. and Mrs. Guy Caccavale
Ms. Geri Caliender
Dr. Tami Carrillo and Mr. Neil Morrow
Ms. Theresa Carrol
Ms. Cathy Casado
Mr. James Case
Mr. and Mrs. Michael Cencula
Ms. Elizabeth Cesario
Ms. Jessica Cestone
Dr. and Mrs. Sung K. Chang
Mr. Jay Chapman
Ms. Laurel Charles
Mr. Robert Chase
Mr. Filemon Chavarria
Ms. Vivian Su Wei Cheng
Mr. Ned Childs
Ms. Pasquale Chirillo
Mr. and Mrs. Phil Chrysler
Ms. Esther Chu
Ms. Corinne Chung
Ms. Lai Lin Chung
Mr. Joseph Ciccone
City of Ward, Parks and Recreation
Mr. Alan Clouse
Ms. Marissa Coker
Mr. Donato Coletta
Ms. Lai Lin Chung
Mr. Joseph Ciccone
Mr. and Mrs. Arthur Gambell
Mr. Antonio Garcia
Mrs. Stacy Garn
Mr. Michael Geanto
Miss Tina Gee
Mrs. Tonya George
Ms. Yvonne George
Ms. Michele Gergans
Mrs. Marilynn Giglio-Knapp
Mr. and Mrs. Peter R. Glasier

Ms. DeAnn Conner
Mr. and Mrs. Richard Cooks
Ms. Shirl Coons
Mr. Michael Coulter Smith
Ms. Judy Craighead
Dr. Miriam Cremer
Ms. Kimberly Czyzowicz
Ms. Susan Dahn
Dr. and Mrs. Robert Darling
Ms. Cathy Davalos
Mr. George Davis
Ms. Marie DeGraeve
Ms. Susan Demers
Mrs. Marti Demetriou
Ms. Martha Den Uyl
Ms. Virginia Diewald
Ms. Beatrice A Dollar
Mr. Rocco Domino
Ms. Angel Downey Price
Mr. Paul Downing
Ms. Mary Dray
Mr. Richard Dutile
Ms. Charlotte Egerton
Mrs. Rita Eisenmann
Ms. Nicole Elizondo
Mr. and Mrs. Tom Evans
Ms. Kristen Felker
Ms. Anne Ferraiuolo
Mr. Aaron Ferris
Mr. Dan Fisk
Ms. Sandy Fitzer
Ms. Nelia S. Fobbs
Ms. Nancy Fortunato
The Foundation of the Greater Miami Jewish Federation
Ms. Amecha Franks
Ms. Julia Franzese
Dr. Rachel Freedman
Ms. Alexis Freeman
Ms. Letitia Frye
Mr. and Mrs. Arthur Gambell
Mr. Antonio Garcia
Mrs. Stacy Garn
Mr. Michael Geanto
Miss Tina Gee
Mrs. Tonya George
Ms. Yvonne George
Ms. Michele Gergans
Mrs. Marilynn Giglio-Knapp
Mr. and Mrs. Peter R. Glasier
Mr. Charles Parker  
Ms. Judith Parnock  
Patrick Automotive Group  
Ms. Chris Pawlowski  
Ms. Lynwood Payne  
Mr. and Mrs. Dennis Pearson  
Mr. and Mrs. Larry Penix  
Mr. Sam Perera  
Mr. and Mrs. Scott Pfeifer  
Mr. Linton Phillips  
Mr. and Mrs. Phillip Picchietti  
Ms. Angela Pierce  
Pioneer Telephone Cooperative  
Ms. Tracy Pitts  
Mr. John Prosperi  
Ms. Cheryl Ramirez  
Mr. Rene Ramirez  
Mr. Eric Ramos  
Rearick Tooling Inc. / JIT  
Mr. Corey Reeder  
Ms. Jennifer Reeves  
Ms. Erin Renzi  
Mr. Dave Riggs  
Ms. Elizabeth Riley  
Mr. Gregg Riley  
Mr. Keith Ripper  
Mr. and Mrs. Joe Rogers  
Mr. and Mrs. Louis Roitblat  
Mrs. Maria Ryan  
Ms. Janette Saenz  
Mr. John Santoro  
Mr. Joseph Scavone  
Mr. Eugene Schempp  
Mr. and Mrs. Bryan Schmidt  
Ms. Lynn Schoenberg  
Mrs. Kim Schwartz  
Mr. Scott Sepulvado  
Mr. David Sewall  
Ms. Pam Sherbia  
Kappa Alpha Sigma, Sigma Gamma Rho Sorority, Inc.  
Mr. Michael Simmons  
Ms. Jeanette Singleton  
Ms. Christy Sisson  
Mrs. Linda Smith  
Ms. Keri Smith  
Ms. Samantha Smith  
Mr. James Snyder  
Mr. Thomas Stavredes  
Ms. Sue Stevens  
Ms. Natalie Stewart  
Ms. Kimberly Stone  
Mr. Robert Stott  
Ms. Janet Summers  
Ms. Rose Swafford  
Mr. Charles Sweeney  
Mr. Robert Swettman  
Mr. and Mrs. James Talbert  
TapQA  
Target Corporation  
Ms. Eileen Taylor  
Mrs. Charlene Taylor  
John and Kristina Telano  
Ms. Emily Thomas  
Ms. Patty Thomas  
Colonel James D. Thompson  
Mr. and Mrs. Stephen Thompson  
Ms. Suzanne Treter  
Ms. Diana Trzaska  
Ms. Danielle Turner  
Mr. and Mrs. Will Turner  
Ms. Sherron Turner  
Ms. Angie Udelhofen  
Ms. Staci Vernick  
Ms. Jennifer Vicidomine  
Ms. and Phyllis Vieira  
Ms. Sandy Vossler  
Ms. Joan Walldan  
Mr. Caprice Walters  
Mr. and Mrs. Corey Walz  
Mrs. Alexandria Waters  
Mr. Mark Watson  
Mr. Gary Weese  
Ms. Elizabeth Welsh  
Ms. McKenna Wesley  
Ms. Maryrose N. White  
Ms. Natalya Williams  
Ms. Kara Williams  
Mr. Grant Williams  
Mr. Jeffrey Williams  
Mr. Samuel Wilson  
Mr. Bruce Wiltbank  
Mr. Kalman Winnick  
Mr. and Mrs. David Winter  
Ms. Lauren Wolf  
Mr. Jeff Wright  
Mr. Randall Wright  
Mr. Robert Wynn  
Ms. Janet Yocum  
Ms. Janine Zaremba

“I have been a volunteer and donate annually in the name of my friend, Kristi, who lost her battle to cancer at the age of 28. Gateway for Cancer Research is important to me because it focuses on funding Phase I and II clinical trials. This is where the greatest impact is in fighting cancer.”

- Molly Stockley, Gateway Volunteer Leader

These donations represent cash gifts from July 1, 2020 through June 30, 2021. Gateway has made every attempt to include and highlight the generosity of our donors. If your name is not included on this list and you made a donation of $100 and above, please let us know.
LEADERSHIP

BOARD OF DIRECTORS

Richard J Stephenson  
CHAIRMAN

Dr. Stacie J. Stephenson  
VICE CHAIR

Fred DeGrandis  
SECRETARY

Timothy Flanigan  
ASSISTANT SECRETARY

Tony Festa  
TREASURER

Amy Belew
Tawnya Bond
Michael Burton
(ex officio)
Joe Caltabiano
Jake Goldstein
Dr. Emanuel Petricoin
Deniz Razon

Edwin Roberson
Mary Lou Smith
Dr. Satish Tadikonda

RESEARCH AND GRANTS COMMITTEE

BOARD OF DIRECTORS

LIAISON
Dr. Emanuel Petricoin
Mary Lou Smith
Deniz Razon

MD/PHD
Dr. Sameek Roychowdhury – Peer Review, Chair
Dr. Edward Kim
Dr. Alberto Pappo
Dr. Tim Fleming
Dr. Ronald Morton
Dr. Jordi A. Rodon
Dr. Vivek Subbiah

PATIENT ADVOCATE
Rich Rieger

ASSOCIATES BOARD

Danny Cameron  
BOARD CO-CHAIR

Catherine Lyman  
BOARD CO-CHAIR

Corey Walz  
TREASURER

David Lauschke  
SECRETARY

Elle Bausch  
COMMUNICATIONS CHAIR

Christi Turner  
MEMBERSHIP & ENGAGEMENT CHAIR

Neira Hot  
MISSION CONNECTION CHAIR

Robert Watson  
SPONSORSHIP CHAIR

MEMBERS

Dan Frett
TJ Gilboy
Emmanuel Lopez
Julia Pfiefer
Shelby Stephenson
Jillian Stevens
Max Strommen
Josh Udelhofen
## FINANCIAL HIGHLIGHTS

### FUNDRAISING REVENUE

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$2,855,488</td>
</tr>
<tr>
<td>Special Events</td>
<td>$528,550</td>
</tr>
<tr>
<td><strong>Total Fundraising Revenue</strong></td>
<td><strong>$3,384,038</strong></td>
</tr>
</tbody>
</table>

### RESEARCH GRANTS

<table>
<thead>
<tr>
<th>Type</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awarded Grant Funds</td>
<td>$7,740,828</td>
</tr>
</tbody>
</table>

### ASSETS

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalent</td>
<td>$3,355,689</td>
</tr>
<tr>
<td>Pledges and Other Receivables</td>
<td>$1,957,197</td>
</tr>
<tr>
<td>Investments</td>
<td>$13,594,909</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>$0</td>
</tr>
<tr>
<td>Interests in Limited Partnerships</td>
<td>$8,350</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$18,916,145</strong></td>
</tr>
</tbody>
</table>

### LIABILITIES

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accrued Grants</td>
<td>$11,712,918</td>
</tr>
<tr>
<td>Accounts Payable</td>
<td>$51,310</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>$800,000</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>$20,260</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>$12,584,488</strong></td>
</tr>
</tbody>
</table>

### NET ASSETS

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net Assets</strong></td>
<td><strong>$6,331,657</strong></td>
</tr>
</tbody>
</table>

### TOTAL LIABILITIES AND NET ASSETS

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td><strong>$18,916,145</strong></td>
</tr>
</tbody>
</table>